Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

4
How To Value Sandridge Permian Trust

2018-07-18 seekingalpha
Sandridge Permian Trust was formed to own royalty interests in the Andrews County, Texas, section of the Permian Basin.
SDOCQ SDRPQ SDRXP SD PER SDRXQ

10
UPDATE 1-SandRidge draws interest from more bidders, including Midstates

2018-06-29 reuters
June 29 (Reuters) - SandRidge Energy Inc has been approached by 26 potential bidders for a buyout of the company or some of its assets, the U.S. shale oil producer said on Friday, days after activist investor Carl Icahn took control of its board.
SDOCQ SDRPQ MPO MPOYQ SDRXP SD SDRXQ

6
Sandridge To Explore Strategic Options, Including Sale

2018-06-29 rigzone
June 29 (Reuters) - U.S. shale oil producer SandRidge Energy Inc said on Friday it plans a strategic review of its business that could include a sale of the company or some of its assets.
SDOCQ SDRPQ SDRXP SD SDRXQ

68
SandRidge Energy: A Bankruptcy Reorg With A Catalyst And 100% Upside

2018-06-26 seekingalpha
Extremely attractive valuation, $725 million PDP PV-10 strip, $1,009 million PV-10 proved, versus roughly a $550 million market cap.
SDOCQ CHK SRCI SDRPQ BCEI SDRXP SD SDRXQ

6
Carl Icahn Won't Bid for SandRidge After Winning Control of Board - Bloomberg

2018-06-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SDOCQ SDRPQ SDRXP SD SDRXQ

669
Westlake Chemical Sees Hammer Chart Pattern: Time to Buy?

2018-06-21 zacks
Westlake Chemical Corporation (WLK - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because WLK recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
SDOCQ BBW WLK SDRPQ AMD SDRXP MPC SD SDRXQ

670
Five Prime Therapeutics Sees Hammer Chart Pattern: Time to Buy?

2018-06-21 zacks
Five Prime Therapeutics, Inc. (FPRX - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because FPRX recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
SDOCQ BBW SDRPQ AMD FPRX SDRXP MPC SD SDRXQ

695
Globalstar Sees Hammer Chart Pattern: Time to Buy?

2018-06-21 zacks
Globalstar, Inc. (GSAT - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because GSAT recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
SDOCQ GSAT BBW SDRPQ AMD SDRXP MPC SD SDRXQ

11
SandRidge Energy (SD) Looks Good: Stock Adds 7.5% in Session

2018-06-20 zacks
SandRidge Energy, Inc. (SD - Free Report) was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 13.9% in the past one-month time frame.
SDOCQ SDRPQ OXY SDRXP SD SDRXQ

10
Icahn Is Said to Have Won Control of Board at SandRidge

2018-06-19 rigzone
(Bloomberg) -- Activist investor Carl Icahn has won control of embattled oil and gas driller SandRidge Energy Inc.’s board based on preliminary results, according to people familiar with the matter.
SDOCQ SDRPQ BCEI SDRXP SD SDRXQ

6
Activist Carl Icahn gains control of board in proxy fight at SandRidge Energy - Channel NewsAsia

2018-06-19 channelnewsasia
Activist investor Carl Icahn on Tuesday won at least four seats on the board of SandRidge Energy , winning a battle for control of the U.S. shale producer that he wants to sell to others or buy himself.
SDOCQ SDRPQ SDRXP SD SDRXQ

6
Activist Carl Icahn gains control of board in proxy fight at SandRidge Energy

2018-06-19 reuters
OKLAHOMA CITY (Reuters) - Activist investor Carl Icahn on Tuesday won at least four seats on the board of SandRidge Energy (SD.N), winning a battle for control of the U.S. shale producer that he wants to sell to others or buy himself.
SDOCQ SDRPQ SDRXP SD SDRXQ

6
Open Letter to SandRidge Energy Stockholders | Carl Icahn

2018-06-18 carlicahn
New York, New York, June 18, 2018 – Today Carl Icahn released the following open letter to stockholders of SandRidge Energy, Inc. (NYSE: SD):
SDOCQ SDRPQ SDRXP SD SDRXQ

6
Open Letter to SandRidge Energy Stockholders | Carl Icahn

2018-06-18 carlicahn
New York, New York, June 18, 2018 – Today Carl Icahn released the following open letter to stockholders of SandRidge Energy, Inc. (NYSE: SD):
SDOCQ SDRPQ SDRXP SD SDRXQ

34
Deals of the day-Mergers and acquisitions

2018-06-15 reuters
June 15 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:
TMUSP EDRVY TMUS SDRPQ LYB TWX TWC SD SDOCQ S EDPR LALWF EDRVF QCOM SDRXP SDRXQ

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...